Yanting Lu1,2†
Ke Ma- 1Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, China
- 2College of TCM, Shandong University of Traditional Chinese Medicine, Jinan, China
- 3School of Pharmaceutical Sciences, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China
Comorbidity between diabetes mellitus (DM) and depression, two chronic and devastating diseases spreading worldwide, has been confirmed by a large body of epidemiological and clinical studies. Due to the bidirectional relationship between DM and depression, this comorbidity leads to poorer outcomes in both conditions. Given the adverse effects and limited effectiveness of the existing therapies for depression associated with diabetes, the development of novel therapeutic drugs with more potency and fewer side effects is still the most important goal. Hence, many researchers have made great efforts to investigate the potential usefulness of traditional Chinese medicine (TCM) and natural products, including natural extracts and purified compounds, in the treatment of comorbid depression in diabetes. Here, we reviewed the related literature on TCM and natural products that can remedy the comorbidity of diabetes and depression and presented them on the basis of their mechanism of action, focusing on shared risk factors, including insulin resistance, oxidative stress and inflammation, and nervous disturbances. In short, this review suggests that TCM and natural products could expand the therapeutic alternatives to ameliorate the association between DM and depressive disorders.
Introduction
Diabetes mellitus (DM) is a prevalent chronic metabolic disease characterized by high blood glucose levels, whereas depression is a mood disorder that is marked by a loss of interest, constant sadness, feelings of guilt or low self-worth, tiredness, disturbed sleep or appetite, and poor concentration (Koye et al., 2018; Lim et al., 2018; Lu et al., 2019). Statistics from the International Diabetes Federation (IDF) revealed that 451 million people lived with DM worldwide in 2017, and these figures are expected to reach 700 million by 2045 (Cho et al., 2018). Moreover, the accelerated pace of life and increased social pressure further lead to a fast-growing incidence of depression. The World Health Organization (WHO) projected that by the year 2030, diabetes would become the seventh leading cause of death worldwide and depression would rank first in global disease burdens (Lepine and Briley, 2011; Roshan and Stanton, 2013).
Considerable evidence supporting a close association between DM and depression has been published. On the one hand, pre-existing depression increases the risk of DM. As early as the 17th century, Thomas Willis, a famous British doctor and anatomist, hypothesized that long-term grief could sometimes cause diabetes. Strong epidemiological evidence provided by longitudinal studies has also indicated a high incidence of DM in individuals who previously developed depression (Knol et al., 2006; Engum, 2007; Golden et al., 2008). In terms of mechanism, the physiological changes elicited by depression (e.g., the release of counter-regulatory hormones, stimulation of sympathetic nervous system release, and altered inflammation state) can induce peripheral insulin resistance, which appears to be the main responsible for DM development (Champaneri et al., 2010). Moreover, poor behavioral factors associated with depression, such as lack of physical inactivity and high caloric intake, can partially contribute to the development of diabetes (Strine et al., 2008).
On the other hand, DM appears to increase the risk of incident or recurrent depression. For example, continuous hyperglycemia in diabetic patients can result in the activation of the hypothalamic-pituitary-adrenal (HPA) axis, which leads to endocrine disorders, characterized by the excess release of cortisol, a hormone that plays an important role in depression (Chiodini et al., 2006; Yi et al., 2010). In addition, several studies have suggested that diagnosed but not undiagnosed diabetes is significantly associated with depression, indicating that the burden of diabetes and/or the psychological stress experienced while coping with diabetes might relate to these depressive symptoms (Knol et al., 2007; Icks et al., 2008; Li et al., 2016). Likewise, epidemiologic studies have demonstrated that the incidence of depression in diabetic patients is two times higher than in the general population (Anderson et al., 2001). Although the relationship between DM and depression has been confirmed, compared with some widely studied complications associated with DM, including retinopathies and atherosclerosis, the comorbidity of diabetes and depression is greatly underestimated due to some circumstances, such as stealthiness, different syndrome types, and difficulties in the assessment of depression.
It should be noted that depression and diabetes each increases the risk of the other in a bidirectional interaction. A few systematic reviews and meta-analysis have estimated that depression accounts for a 60% increase in diabetes risk, and diabetes was estimated to account for a 24% increased risk of depression (Mezuk et al., 2008; Rubin et al., 2008; Yu et al., 2015; Khaledi et al., 2019; Nouwen et al., 2019). The comorbidity of DM and depression thus leads to higher medical care costs, worse prognosis, increased severity, decline in quality of life, and increased treatment resistance and mortality for both diseases (Pradeepa and Mohan, 2017).
In case of comorbid depression with diabetes, a key therapeutic aim is to relieve depression and improve blood glucose levels (Zhang and Feng, 2016). Clinically, it is generally considered that comorbid diabetes and depression should be treated with a combination of hypoglycemic drugs with antidepressants (Li et al., 2018). Although antidepressants are employed for pharmacological interventions in DM, their effectiveness in the improvement of depressive symptoms is moderate (Petrak et al., 2015). Apart from the documented adverse reactions like cardiometabolic effects, a large number of antidepressant agents, such as mirtazapine, can increase appetite in patients and result in a high risk of weight gain, which is not conducive to the control of blood sugar (Gill et al., 2020). Therefore, it is urgent to explore and discover novel agents with better efficacy and fewer adverse reactions. Given the multicomponent and multitarget characteristics of traditional Chinese medicine (TCM) as well as the value of natural products (natural extracts and single isolated compounds) for drug discovery, a growing body of research has investigated and established therapeutic effects and related mechanisms of multiple TCM interventions and natural products on diabetic depression (Zheng et al., 2020). We summarized these TCM and natural products and their effects against the comorbidity of diabetes and depression (Tables 1–3 and Figure 1) and classified them according to their mechanism of action, as outlined below.
TABLE 1. TCM formulae with effects on depression associated with diabetes.
TABLE 2. Natural extracts with effects on depression associated with diabetes.
TABLE 3. Natural compounds with effects on depression associated with diabetes.
FIGURE 1. Schematic of TCM and natural products against comorbid depression with diabetes and their related mechanism.
TCM and Natural Products with Effects on Insulin Resistance
Insulin Resistance and Comorbid Depression with Diabetes
Insulin resistance caused by the decrease in insulin sensitivity disrupts the entry of glucose into muscle, liver, and adipose tissue, which eventually leads to diabetes. Physiologically, the interaction of insulin with the insulin receptor (InsR) on the cell membrane activates an intrinsic tyrosine protein kinase, which autophosphorylates the receptor as well as downstream insulin receptor substrates (IRSs) (Jung and Choi, 2014). The phosphorylation of IRS proteins on tyrosine residues activates downstream PI3K-AKT signaling, which alters the activity or expression of several key factors involved in glucose metabolism and glycogen/lipid/protein synthesis, such as glycogen synthase kinase (GSK)-3β, regulatory element-binding protein-1c (SREBP1-c), and glucose transporter (GLUT) translocation, especially GLUT4 (Beale, 2013). The insulin-mediated IRS-PI3K-AKT signaling pathway is therefore a key pathway affecting the metabolic effects of insulin and is usually dysregulated in people with diabetes (Yaribeygi et al., 2019). Moreover, impairment of insulin signaling is also present in high-fat diet (HFD)-induced diabetic rats with depressive-like behavior (Papazoglou et al., 2015). Furthermore, a meta-analysis of 21 studies found a statistically significant association between depression and insulin resistance, and this positive association suggests a biological link between depression and DM (Kan et al., 2013). Insulin receptors are expressed throughout the brain, and several studies have indicated the ability of insulin to affect the nervous system (Porte et al., 2002; Banks et al., 2012). The knockdown of insulin receptors in the hypothalamus of rats triggers depressive behaviors (Kleinridders et al., 2015). Consistently, insulin administration improves working memory in both human and animal studies (Gupta et al., 2014a; Zhao et al., 2019), confirming that insulin is involved in hippocampal neurogenesis linked with depression.
Considering that insulin resistance is a shared metabolic abnormality among many individuals with DM and depression, repurposing therapies approved for treating insulin resistance might be useful in the treatment of comorbid DM and depression (Hamer et al., 2019). A clinical study of 488 patients with major depression found that selective agonists of the nuclear transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ), which are used for the treatment of insulin resistance-related diabetes, exhibit significant antidepressant properties by virtue of their ability to ameliorate insulin resistance and glucose tolerance (Colle et al., 2017). Further, the classic antidiabetic drug metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice (Zemdegs et al., 2019), suggesting that the management of depression-associated diabetes through targeting insulin resistance is effective and practicable.
TCM and Natural Products for Treating Insulin Resistance Associated with Comorbid Depression and Diabetes
Decoction of Pinellia and Magnolia Bark (Banxia-Houpu decoction) is a well-known formula of TCM consisting of Pinellia ternata (Thunb.) Makino, Magnolia officinalis Rehd. et Wils., Smilax glabra Roxb., Perilla frutescens (L.) Britt., and Zingiber officinale Rosc. In chronic unpredictable mild stress (CUMS) rats, decoction of Pinellia and Magnolia Bark has been found to regulate InsR/IRS1/AKT insulin signaling, to decrease the level of serum corticosterone (CORT), and to improve glucose tolerance in both peripheral liver and brain regions (Jia et al., 2017). Clinical trials have showed that Ease Powder of Moutan Bark and Cape Jasmine Fruit (Danzhi Xiaoyao powder, DZXYP) has the ability to regulate glucose and improve the symptoms of depression and insomnia (Zhang and Xiao, 2008). Likewise, a meta-analysis of DZXYP for type 2 DM complicating depression suggested that treatment with DZXYP improved fasting blood glucose, HbA1c, Hamilton depression scale score, and self-rating depression scale score (Zhang et al., 2017). Mechanism research revealed that DZXYP alleviates diabetes-associated depression through the IRS2-PI3K signaling pathway in the liver tissues of rats (Wang et al., 2013). Two other studies verified the hypoglycemic and antidepressant effects of Glucose-Lowering and Relieving Depression Decoction for Tonifying the Kidney-yin (Zuogui Jiangtang Jieyu prescription, ZGJTJY) (Wang et al., 2014; Yang et al., 2020), showing that ZGJTJY can effectively regulate the insulin signaling pathway and improve insulin resistance in the hippocampus of rats with diabetes-related depression (Yang et al., 2020). In line with these observations, the hydroalcoholic extract of Urtica dioica L. leaves was found to reverse the decline in hippocampal GLUT4 expression and plasma CORT induced by dexamethasone, which correlated with its ability to improve hyperglycemia and associated depressive-like behavior (Patel and Udayabanu, 2014) (Tables 1, 2; Figure 1).
A large number of monomeric compounds possess hypoglycemic and antidepressant properties via different mechanisms. Among them, curcumin and quercetin are representative purified compounds capable of improving insulin resistance. Curcumin has been reported to enhance insulin sensitivity and increase the hepatic glycogen content by upregulating the phosphorylation of IRS-1 and AKT and inhibiting GSK-3β in rats with depression complicated by insulin resistance using a 12-week exposure to chronic mild stress, which were conducive to reversing the metabolic abnormalities and depressive-like behaviors (Shen et al., 2017). In the Porsolt forced swimming-induced behavioral despair test, quercetin treatment was found to reduce the immobility period and to reverse depressive-like behavior in a dose-dependent manner in streptozotocin (STZ)-induced diabetic mice (Anjaneyulu et al., 2003). Further study has indicated that quercetin administration in male Swiss albino mice can significantly attenuate insulin resistance and elevate hippocampal GLUT4 levels (Mehta et al., 2017). Similarly, umbelliferone treatment (20 and 40 mg/kg, for 3 weeks) in CUMS-induced rats effectively improved depression symptoms and maintained blood glucose balance. Western blot analysis demonstrated that umbelliferone administration markedly increases the phosphorylation of InsR, IRS-1, AKT, PI3K, and GSK-3β, suggesting an ameliorative effect of umbelliferone against insulin resistance (Su et al., 2016) (Table 3; Figure 1).
TCM and Natural Products Linked with Oxidative Stress and Inflammation
The Role of Oxidative Stress and Inflammation in Comorbid Depression with DM
Oxidative stress and inflammation interact in the pathophysiology of both DM and depression. For instance, the elevated release of ROS, a characteristic of oxidative stress, not only causes direct damage to the insulin-producing pancreatic β-cells but also results in inflammatory processes, immune activation, increased oxidation of monoaminergic neurotransmitters, and lipid peroxidation, all of which correlate with DM and depression (Gerber and Rutter, 2017; Forrester et al., 2018; Reus et al., 2019). Similarly, increased concentrations of cytokines resulting from inflammatory processes also lead to the apoptosis of pancreatic β-cells and insulin resistance as well as enhanced oxidative stress in the brain and activation of the HPA axis and the tryptophan-kynurenine pathway, contributing to the risk of coexistence of diabetes and depression symptoms (Moulton et al., 2015). There is evidence that patients with diabetes or depression have significantly increased levels of oxidative stress markers including malondialdehyde (MDA), F2-isoprostanes, and 8-OH 2-deoxyguanosine (8-OHdG), as well as proinflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). In addition, decrease in the content or activity of important antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT), has also been observed (Myint et al., 2005; Ballak et al., 2015; Lindqvist et al., 2017; Luc et al., 2019).
Moreover, injection of cytokines in animals and humans can induce depression-like symptoms and diabetes (Horikawa et al., 2003; Sauter et al., 2015; Abdul Aziz et al., 2016). Consistent with these findings, clinical trials have indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) and cytokine inhibitors may yield antidepressant effects (Kohler et al., 2016). Treatment with antioxidants including N-acetylcysteine and deferoxamine ameliorates diabetes-induced depressive-like behavior (Reus et al., 2016). Thus, blockade of oxidative stress and targeting the proinflammatory signaling pathway might be potential therapeutic strategies for comorbid depression in diabetes.
TCM and Natural Products with Antioxidative Stress and Inflammation Effects against Comorbid Depression and Diabetes
The antioxidative stress and anti-inflammatory activities of TCM and natural extracts and compounds have been widely explored. In this sense, decoction of Pinellia and Magnolia Bark was found to inhibit NLRP3 inflammasome activation in a number of tissues, such as the liver, hypothalamus, hippocampus, and prefrontal cortex, which contributes to the prevention of hyperglycemia and depressive-like behavior in CUMS rats (Jia et al., 2017). The ZGJTJY treatment mentioned above was found to reduce IL-1β and TNF-α levels in the hippocampus in the rat model of diabetes complicated by depression induced by high-fat emulsion, injection of STZ via coccygeal vein, and chronic stress (Yang et al., 2018). Inspired by a meta-analysis showing the effectiveness and safety of Bupleurum Powder for Relieving Liver-qi (Chaihu-Shugan San, CHSGS) in the clinical treatment of depression (Wang et al., 2012b), a recent study by Jia et al. further confirmed that CHSGS improves glucose tolerance in the rat model of depression. Briefly, this formula was found to improve insulin signaling and to suppress both the TLR4/MyD88/NF-κB pathway and the activation of NLRP3 inflammasome, thereby reducing blood glucose levels and ameliorating depressive-like behaviors through inhibiting liver-brain inflammation axis (Jia et al., 2018). The previous study established a relatively precise effect of the Chinese Angelica Decoction for Replenishing Blood (Danggui-Buxue decoction, DBD) on DM with depression (Wang et al., 2018), and investigation of the mechanisms showed that DBD reduces serum levels of inflammatory factors such as TNF-α, CRP, IL-6, and IL-8, thereby inhibiting the systemic inflammatory response and achieving the positive regulation of DM complicated with depression (Wang et al., 2020a) (Table 1; Figure 1).
In the same way, hydroalcoholic extracts of Rosa canina L. fruit, an Iranian traditional medicinal herb with antioxidant activities, were found to enhance the attenuation of depressive-like behavior and recognition memory impairment through regulation of the oxidative stress marker MDA and total antioxidant capacity (TAC) in diabetic mice (Sadigh-Eteghad et al., 2011; Farajpour et al., 2017). Likewise, Aloe vera gel was found to increase activities of hippocampal SOD and CAT and to reduce MDA levels in the hippocampus tissue of STZ-induced diabetic rats, thus improving oxidative status and behavioral deficits (Tabatabaei et al., 2017). In STZ-induced diabetic rats, garlic (Allium sativum L.) (0.5 g/kg, gavage, 10 days) treatment also decreased the total duration of immobility, attenuated MDA levels, and increased SOD and glutathione peroxidase (GSH-Px) activities, indicating that garlic alleviates depression-related behaviors partly by attenuating brain oxidative stress (Rahmani et al., 2020). Additionally, extracts of Urtica dioica L. were proven to be effective for anxiety- and depressive-like behavior mediated by DM via decreasing the expression of TNF-α in the hippocampal area (Patel et al., 2018) (Table 2; Figure 1).
Numerous phytochemical molecules with various pharmacological effects exhibit antidepressant activity and improve glucose tolerance through the modulation of oxidative stress and/or inflammatory response. For instance, the anxiolytic-like and neuroprotective effects of resveratrol, a stilbenoid isolated from multiple medicinal herbs, correlate with its ability to strengthen the antioxidant action of SOD enzymes and to attenuate the expression of TNF-α, IL-6, and NF-κB in the hippocampus of diabetic rats (Jing et al., 2013; Sahin et al., 2019). Two phenolic compounds, ellagic acid and protocatechuic acid, were able to suppress inflammatory biomarkers and ameliorate diabetes-induced cognitive deficits reflected by the improvement of locomotor activity (Adedara et al., 2019; Farbood et al., 2019). In diabetic db/db mice, gastrodin administration and treatment with ginsenoside compound K were found to significantly attenuate blood glucose levels and to reverse behavioral impairment and cognitive dysfunction due to the inhibitory effects of these compounds on endoplasmic reticulum (ER) stress and NLRP3 inflammasome activation in the hippocampus (Ye et al., 2018; Li et al., 2020). Similar outcomes also have been observed for several molecules from medicinal and edible plants. Naveen Shivaved et al. revealed that ascorbic acid, which is abundant in fresh fruits and vegetables, ameliorates oxidative stress and inflammatory response by reducing catalase levels and increasing SOD content, CAT activity, and IL-10 levels in the prefrontal cortex of diabetic rats, indicating the therapeutic potential of ascorbic acid against diabetes comorbid depression (Shivavedi et al., 2019). In addition, studies by Zhou et al. showed that carotenoids, including astaxanthin and zeaxanthin, downregulate IL-6 and IL-1β in the hippocampus and protect neurons from hyperglycemic damage, implicating that depression can be prevented by astaxanthin and zeaxanthin through the inhibition of hippocampal inflammation in diabetic mice (Zhou et al., 2017; Zhou et al., 2018). Finally, β-caryophyllene, a natural sesquiterpene found in some food condiments, was proved to attenuate the expression of cytokines and depressive-like behavior in experimental diabetic mice subjected to the marble test, forced swim test, and tail suspension test (Aguilar-Avila et al., 2019) (Table 3; Figure 1).
TCM and Natural Products with Effects on Changes in Nervous System
Nervous System Changes and Comorbid Depression with Diabetes
In patients with DM and depressive disorders, a wide variety of disturbances may affect the central nervous systems, including the overactivation of the HPA axis, decreased monoamine neurotransmitters, and dysfunctional brain-derived neurotrophic factor (BDNF) (Donato, 2012; Biessels and Reijmer, 2014). Firstly, patients with diabetic depression present significant HPA axis dysfunction as well as higher levels of cortisol than control patients (Joseph and Golden, 2017). Hyperactivity of the HPA axis results in elevated levels of cortisol, which impairs the ability of insulin to transfer the intracellular glucose transporter GLUT4 to cell membrane and hampers neurogenesis in the hippocampus (Coderre et al., 1996; Moulton et al., 2015; Shirazi et al., 2015). Therefore, the chronic exposure to excess cortisol eventually leads to insulin resistance and concomitant metabolic syndromes including type 2 diabetes as well as mental disorders including depression (Rhyu et al., 2019). Furthermore, the decreased or insufficient secretion of monoamine transmitters in the brain, such as norepinephrine (NE), dopamine (DA), γ-aminobutyric (GABA), and serotonin (5-HT), is also a major cause of comorbid diabetic depression (Hashim et al., 2016; Ma et al., 2019; Mukherjee and Chaturvedi, 2019; Zhang et al., 2020). Experimental studies have revealed that impairment of 5-HT causes nerve cell damage and decreases neurogenesis, leading to anxiety and depression (Mahar et al., 2014; Yohn et al., 2017). In addition to acting as a neurotransmitter that regulates the function of the central nervous system, 5-HT also exerts multiple physiological functions in the periphery, and several studies have revealed the relationship between the peripheral 5-HT system and some diseases including type 2 diabetes (Fu et al., 2018). Two studies by Gupta et al. showed the counteractive effect of 5HT3 receptor antagonists against diabetes-induced depressive phenotypes in STZ-induced diabetic mice, further revealing the implication of the serotonergic system in diabetic depression (Gupta et al., 2014b; Gupta et al., 2016). As a neurotrophic factor, BDNF promotes the proliferation, remodeling, and regeneration of nerve cells and thus regulates neuroplasticity. Serum BDNF concentrations have been found to be decreased in patients with depression and diabetes (Karege et al., 2005; Krabbe et al., 2007). Convincing evidence supports the view that BDNF plays an important role in the pathogenesis of depression and diabetes.
Briefly, BDNF may improve glucose metabolism and reduce food consumption by modulating the production of insulin, leptin, ghrelin, neurotransmitters/neuropeptides, and proinflammatory cytokines associated with energy homeostasis. Clinical studies have shown that depressive states could be reversed by administration of BDNF (Wang et al., 2012a). Moreover, BDNF is positively regulated by the ER chaperon sigma-1 receptor (S1R), and studies have shown that fluvoxamine, a S1R agonist, ameliorates depression-like behaviors in DM-induced depression (Lenart et al., 2016). In short, the repair of the nervous system serves as a therapeutic regimen for the prevention of DM-associated depression.
TCM and Natural Products Targeting Nervous System Changes Associated with Comorbid Depression and Diabetes
As mentioned above, changes in the nervous system are critical for the development of diabetic depression. From this perspective, Decoction for Tonifying Kidney and Relieving Depression (Yishen Jieyu decoction) improves HPA axis function and decreases the cortisol level in patients with DM-related depression and TCM syndrome, which is diagnostic of kidney deficiency and liver-qi stagnation (Lu, 2012). HPA axis disorder also causes an abnormal increase in CORT in rodents, which is closely related to two essential proteins expressed in the hippocampus, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and glucocorticoids (GR) (Wang et al., 2015; Meijer et al., 2018). The aforementioned ZGJTJY (10.26 g/kg) also increases motor activities and improves cognitive ability in rats with diabetes-related depression by increasing the expression of GR and decreasing 11β-HSD1 (Wang et al., 2015; Yang et al., 2019). Taking into consideration the observed effectiveness of Formula for Soothing Liver and Tonifying Spleen (Shugan Jianpi formula, SGJP) in the treatment of diabetes-related depression (Wang, 2008; Li, 2017), a recent study by Lei et al. indicated that SGJP improves depressive symptoms in CUMS and STZ-induced rats by upregulating the expression of BDNF mRNA and protein (Lei et al., 2017). Similarly, BDNF elevation is yet another mechanism of DBD against comorbid depression and diabetes. In CUMS-induced spontaneous diabetic rats, DBD (4.0 g/kg) and its main active ingredient ferulic acid (1.36 mg/kg) could increase serum and hippocampal BDNF levels to improve depression-like behavior, an effect that might relate to the activation of the CREB/TrkB signaling pathway (Wang et al., 2020b) (Table 1; Figure 1).
Likewise, the methanolic extract of Brassica juncea leaves (100, 200, and 400 mg/kg/day, p.o.) has been found to display antidepressant activity in alloxan monohydrate-induced diabetic rodents and to compensate for the low levels of DA, NE, and 5-HT in the brain of diabetic rats (Thakur et al., 2014). Cannabidiol (CBD), a non-psychotomimetic compound derived from Cannabis sativa, has been identified as a promising small molecule for the treatment of psychiatric disorders. It is reported that CBD might be effective in the treatment of diabetic depression, and this effect seems to be mediated by the activation of the serotonergic system through the 5-HT1A receptor (de Morais et al., 2018; Jesus et al., 2019). In the diabetic rat model induced by high-fat diet and low-dose STZ, treatment of Morus alba L. and the combination of Pueraria lobata (Willd.) Ohwi and Crataegus pinnatifida Bunge could reduce blood glucose levels and attenuate depressive-like behaviors, which might be partially ascribed to the upregulated BDNF expression in the prefrontal cortex (Luo et al., 2016; Ye et al., 2017). In addition, restoration of BDNF is also involved in the geniposide- and ellagic acid-mediated alleviation of depression-like behavior in STZ-evoked diabetic mice (Wang et al., 2016; Farbood et al., 2019) (Tables 2, 3; Figure 1).
Conclusion
Recently, some hospital-based cross-sectional studies have further clarified the comorbidity between DM and depression (Khassawneh et al., 2020; Tusa et al., 2020). In this review, we summarized TCM formulae and natural products with antidiabetic depression activities as well as several mechanisms related to their activities. Although the TCM and natural bioactive products discussed here greatly expand the spectrum of potential candidates for the prevention and treatment of the comorbidity of depression with DM, their efficacy should be further evaluated in randomized, double-blinded, and placebo-controlled clinical trials. Moreover, the active components in TCM or natural extracts, such as ZGJTJY and hydroalcoholic extract of Urtica dioica leaves, remain unclear in the literature. More importantly, the underlying mechanisms in most studies were only partially understood and mainly focused on changes in signaling pathways (Jia et al., 2018), cytokines and neurotransmitters content (Thakur et al., 2014; Aguilar-Avila et al., 2019; Farbood et al., 2019), and antioxidant enzyme activity (Rahmani et al., 2020). The target(s) with which the bioactive compounds interact and how the changes are triggered should be studied in depth. For example, omics technologies and network pharmacology might be helpful for the identification or prediction of the target of purified compounds or active ingredients in TCM or natural extracts, which may in turn enhance our understanding of the molecular mechanisms underlying the comorbidity between DM and depression. In addition, some studies on natural extracts and purified compounds from medicinal and edible plants suggest the potential of diet or nutritional therapy as an adjuvant for treating depression commonly associated with diabetes (Shen et al., 2017; Shivavedi et al., 2019; Rahmani et al., 2020). Overall, this review provides an important theoretical basis for therapeutic alternatives and potential intervention strategies to ameliorate comorbid DM and depression and broadens the scope of knowledge to guide future studies on this subject.
Author Contributions
YL, TA, and KM were involved in the development of the subject matter, drafting of the article, design of the figure, critical revision of the article, and final approval of the version to be published; HT and XG were involved in critical revision of the article and final approval of the version to be published; SW and FW were involved in the development of the subject matter, drafting of the article, critical revision of the article, and final approval of the version to be published. All authors have read and approved the final version of the manuscript.
Funding
This study was supported by the Shandong Provincial Natural Science Foundation (ZR2020QH329, ZR2019BH027 and ZR2019ZD23), Shandong Province Universities’ Development Plan for Youth Innovation Teams (2019-9-202, 2019-201, and 2019KJK013), National Nature Science Foundation of China (81903948), and Shandong Province University Scientific Research Project (J18KZ014).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The authors thank Dr. Z Zhang for a thoughtful review of the content related to Chinese medicine.
Glossary
11β-HSD1 11β-hydroxysteroid dehydrogenase type 1
5-HT serotonin
8-OHdG 8-OH 2-deoxyguanosine
BDNF brain-derived neurotrophic factor
CAT catalase
NSAIDs nonsteroidal anti-inflammatory drugs
CBD cannabidiol
CHSGS Chaihu-Shugan San or Bupleurum Powder for Relieving Liver-qi
CORT corticosterone
CUMS chronic unpredictable mild stress;
DA dopamine
DBD Danggui-Buxue decoction or Chinese Angelica Decoction for Replenishing Blood
DM diabetes mellitus
DZXYP Danzhi Xiaoyao powder or Ease Powder of Moutan Bark and Cape Jasmine Fruit
ER endoplasmic reticulum
GLUT glucose transporter
GR glucocorticoid
GSH-Px glutathione peroxidase
GSK glycogen synthase kinase
HFD high-fat diet
HPA hypothalamic-pituitary-adrenal
IDF International Diabetes Federation
IL-1 interleukin-1
IL-6 interleukin-6
InsR insulin receptor
IRS insulin receptor substrates
MDA malondialdehyde
NE norepinephrine
PPAR-γ peroxisome proliferator-activated receptor-gamma;
S1R sigma-1 receptor
SGJP Shugan Jianpi formula or Formula for Soothing Liver and Tonifying Spleen
SOD superoxide dismutase
SREBP1-c sterol regulatory element-binding protein-1c
STZ streptozotocin
TAC total antioxidant capacity
TCM traditional Chinese medicine
TNF-α tumor necrosis factor-alpha
WHO World Health Organization
ZGJTJY Zuogui Jiangtang Jieyu prescription
References
Abdul Aziz, S. H., John, C. M., Mohamed Yusof, N. I., Nordin, M., Ramasamy, R., Adam, A., et al. (2016). Animal model of gestational diabetes mellitus with pathophysiological resemblance to the human condition induced by multiple factors (nutritional, pharmacological, and stress) in rats. BioMed Res. Int. 2016, 9704607. doi:10.1155/2016/9704607
Adedara, I. A., Fasina, O. B., Ayeni, M. F., Ajayi, O. M., and Farombi, E. O. (2019). Protocatechuic acid ameliorates neurobehavioral deficits via suppression of oxidative damage, inflammation, caspase-3 and acetylcholinesterase activities in diabetic rats. Food Chem. Toxicol. 125, 170–181. doi:10.1016/j.fct.2018.12.040
Aguilar-Avila, D. S., Flores-Soto, M. E., Tapia-Vazquez, C., Pastor-Zarandona, O. A., Lopez-Roa, R. I., and Viveros-Paredes, J. M. (2019). Beta-caryophyllene, a natural sesquiterpene, attenuates neuropathic pain and depressive-like behavior in experimental diabetic mice. J. Med. Food. 22 (5), 460–468. doi:10.1089/jmf.2018.0157
Anderson, R. J., Freedland, K. E., Clouse, R. E., and Lustman, P. J. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 24 (6), 1069–1078. doi:10.2337/diacare.24.6.1069
Anjaneyulu, M., Chopra, K., and Kaur, I. (2003). Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. J. Med. Food. 6 (4), 391–395. doi:10.1089/109662003772519976
Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., and van Diepen, J. A. (2015). IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 75 (2), 280–290. doi:10.1016/j.cyto.2015.05.005
Banks, W. A., Owen, J. B., and Erickson, M. A. (2012). Insulin in the brain: there and back again. Pharmacol. Ther. 136 (1), 82–93. doi:10.1016/j.pharmthera.2012.07.006
Beale, E. G. (2013). Insulin signaling and insulin resistance. J. Invest. Med. 61 (1), 11–14. doi:10.2310/JIM.0b013e3182746f95
Biessels, G. J., and Reijmer, Y. D. (2014). Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?. Diabetes. 63 (7), 2244–2252. doi:10.2337/db14-0348
Champaneri, S., Wand, G. S., Malhotra, S. S., Casagrande, S. S., and Golden, S. H. (2010). Biological basis of depression in adults with diabetes. Curr. Diabetes Rep. 10 (6), 396–405. doi:10.1007/s11892-010-0148-9
Chiodini, I., Di Lembo, S., Morelli, V., Epaminonda, P., Coletti, F., Masserini, B., et al. (2006). Hypothalamic-pituitary-adrenal activity in type 2 diabetes mellitus: role of autonomic imbalance. Metabolism. 55 (8), 1135–1140. doi:10.1016/j.metabol.2006.04.010
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., et al. (2018). IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271–281. doi:10.1016/j.diabres.2018.02.023
Coderre, L., Vallega, G. A., Pilch, P. F., and Chipkin, S. R. (1996). In vivo effects of dexamethasone and sucrose on glucose transport (GLUT-4) protein tissue distribution. Am. J. Physiol. 271 (4), E643–E648. doi:10.1152/ajpendo.1996.271.4.E643
Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., et al. (2017). PPAR-gamma agonists for the treatment of major depression: a review. Pharmacopsychiatry. 50 (2), 49–55. doi:10.1055/s-0042-120120
de Morais, H., Chaves, Y. C., Waltrick, A. P. F., Jesus, C. H. A., Genaro, K., Crippa, J. A., et al. (2018). Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. Neurosci. Lett. 682, 62–68. doi:10.1016/j.neulet.2018.06.006
Donato, J. (2012). The central nervous system as a promising target to treat diabetes mellitus. Curr. Top. Med. Chem. 12 (19), 2070–2081. doi:10.2174/156802612804910214
Engum, A. (2007). The role of depression and anxiety in onset of diabetes in a large population-based study. J. Psychosom. Res. 62 (1), 31–38. doi:10.1016/j.jpsychores.2006.07.009
Farajpour, R., Sadigh-Eteghad, S., Ahmadian, N., Farzipour, M., Mahmoudi, J., and Majdi, A. (2017). Chronic administration of Rosa canina hydro-alcoholic extract attenuates depressive-like behavior and recognition memory impairment in diabetic mice: a possible role of oxidative stress. Med. Princ. Pract. 26 (3), 245–250. doi:10.1159/000464364
Farbood, Y., Rashno, M., Ghaderi, S., Khoshnam, S. E., Sarkaki, A., Rashidi, K., et al. (2019). Ellagic acid protects against diabetes-associated behavioral deficits in rats: possible involved mechanisms. Life Sci. 225, 8–19. doi:10.1016/j.lfs.2019.03.078
Forrester, S. J., Kikuchi, D. S., Hernandes, M. S., Xu, Q., and Griendling, K. K. (2018). Reactive oxygen species in metabolic and inflammatory signaling. Circ. Res. 122 (6), 877–902. doi:10.1161/CIRCRESAHA.117.311401
Fu, J., Li, C., Zhang, G., Tong, X., Zhang, H., Ding, J., et al. (2018). Crucial roles of 5-HT and 5-HT2 receptor in diabetes-related lipid accumulation and pro-inflammatory cytokine generation in hepatocytes. Cell. Physiol. Biochem. 48 (6), 2409–2428. doi:10.1159/000492656
Gerber, P. A., and Rutter, G. A. (2017). The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxidants Redox Signal. 26 (10), 501–518. doi:10.1089/ars.2016.6755
Gill, H., Gill, B., El-Halabi, S., Chen-Li, D., Lipsitz, O., Rosenblat, J. D., et al. (2020). Antidepressant medications and weight change: a narrative review. Obesity. 28 (11), 2064–2072. doi:10.1002/oby.22969
Golden, S. H., Lazo, M., Carnethon, M., Bertoni, A. G., Schreiner, P. J., Diez Roux, A. V., et al. (2008). Examining a bidirectional association between depressive symptoms and diabetes. J. Am. Med. Assoc. 299 (23), 2751–2759. doi:10.1001/jama.299.23.2751
Gupta, D., Kurhe, Y., and Radhakrishnan, M. (2014a). Antidepressant effects of insulin in streptozotocin induced diabetic mice: modulation of brain serotonin system. Physiol. Behav. 129, 73–78. doi:10.1016/j.physbeh.2014.02.036
Gupta, D., Radhakrishnan, M., and Kurhe, Y. (2014b). Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. Eur. J. Pharmacol. 744, 59–66. doi:10.1016/j.ejphar.2014.09.041
Gupta, D., Thangaraj, D., and Radhakrishnan, M. (2016). A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: modulation of serotonergic system. Behav. Brain Res. 297, 41–50. doi:10.1016/j.bbr.2015.10.007
Hamer, J. A., Testani, D., Mansur, R. B., Lee, Y., Subramaniapillai, M., and McIntyre, R. S. (2019). Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression. Exp. Neurol. 315, 1–8. doi:10.1016/j.expneurol.2019.01.016
Hashim, N. A., Ariaratnam, S., Salleh, M. R., Said, M. A., and Sulaiman, A. H. (2016). Depression and associated factors in patients with type 2 diabetes mellitus. East Asian Arch. Psychiatry. 26 (2), 77–82
Horikawa, N., Yamazaki, T., Izumi, N., and Uchihara, M. (2003). Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen. Hosp. Psychiatr. 25 (1), 34–38. doi:10.1016/s0163-8343(02)00239-6
Icks, A., Kruse, J., Dragano, N., Broecker-Preuss, M., Slomiany, U., Mann, K., et al. (2008). Are symptoms of depression more common in diabetes? Results from the Heinz Nixdorf Recall study. Diabet. Med. 25 (11), 1330–1336. doi:10.1111/j.1464-5491.2008.02585.x
Jesus, C. H. A., Redivo, D. D. B., Gasparin, A. T., Sotomaior, B. B., de Carvalho, M. C., Genaro, K., et al. (2019). Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Res. 1715, 156–164. doi:10.1016/j.brainres.2019.03.014
Jia, K. K., Pan, S. M., Ding, H., Liu, J. H., Zheng, Y. J., Wang, S. J., et al. (2018). Chaihu-shugan san inhibits inflammatory response to improve insulin signaling in liver and prefrontal cortex of CUMS rats with glucose intolerance. Biomed. Pharmacother. 103, 1415–1428. doi:10.1016/j.biopha.2018.04.171
Jia, K. K., Zheng, Y. J., Zhang, Y. X., Liu, J. H., Jiao, R. Q., Pan, Y., et al. (2017). Banxia-houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain. J. Ethnopharmacol. 209, 219–229. doi:10.1016/j.jep.2017.08.004
Jing, Y. H., Chen, K. H., Kuo, P. C., Pao, C. C., and Chen, J. K. (2013). Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol. Neuroendocrinology. 98 (2), 116–127. doi:10.1159/000350435
Joseph, J. J., and Golden, S. H. (2017). Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1391 (1), 20–34. doi:10.1111/nyas.13217
Jung, U. J., and Choi, M. S. (2014). Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15 (4), 6184–6223. doi:10.3390/ijms15046184
Kan, C., Silva, N., Golden, S. H., Rajala, U., Timonen, M., Stahl, D., et al. (2013). A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 36 (2), 480–489. doi:10.2337/dc12-1442
Karege, F., Bondolfi, G., Gervasoni, N., Schwald, M., Aubry, J. M., and Bertschy, G. (2005). Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatr. 57 (9), 1068–1072. doi:10.1016/j.biopsych.2005.01.008
Khaledi, M., Haghighatdoost, F., Feizi, A., and Aminorroaya, A. (2019). The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 56 (6), 631–650. doi:10.1007/s00592-019-01295-9
Khassawneh, A. H., Alzoubi, A., Khasawneh, A. G., Abdo, N., Abu-Naser, D., Al-Mistarehi, A. H., et al. (2020). The relationship between depression and metabolic control parameters in type 2 diabetic patients: a cross-sectional and feasibility interventional study. Int. J. Clin. Pract. e13777. doi:10.1111/ijcp.13777
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., et al. (2015). Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. United States. 112 (11), 3463–3468. doi:10.1073/pnas.1500877112
Knol, M. J., Heerdink, E. R., Egberts, A. C., Geerlings, M. I., Gorter, K. J., Numans, M. E., et al. (2007). Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom. Med. 69 (4), 300–305. doi:10.1097/PSY.0b013e31805f48b9
Knol, M. J., Twisk, J. W., Beekman, A. T., Heine, R. J., Snoek, F. J., and Pouwer, F. (2006). Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 49 (5), 837–845. doi:10.1007/s00125-006-0159-x
Kohler, O., Krogh, J., Mors, O., and Benros, M. E. (2016). Inflammation in depression and the potential for anti-inflammatory treatment. Curr. Neuropharmacol. 14 (7), 732–742. doi:10.2174/1570159x14666151208113700
Koye, D. N., Magliano, D. J., Nelson, R. G., and Pavkov, M. E. (2018). The global epidemiology of diabetes and kidney disease. Adv. Chron. Kidney Dis. 25 (2), 121–132. doi:10.1053/j.ackd.2017.10.011
Krabbe, K. S., Nielsen, A. R., Krogh-Madsen, R., Plomgaard, P., Rasmussen, P., Erikstrup, C., et al. (2007). Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 50 (2), 431–438. doi:10.1007/s00125-006-0537-4
Lei, Y., Xu, R., and Li, H. (2017). Effect of shugan jianpi prescription on the expression of BDNF mRNA and protein levels in the rats with diabetic depression. J. Liaoning Univ. Tradit. Chin. Med. 19 (1), 31–34. doi:10.13194/j.issn.1673-842x.2017.01.009
Lenart, L., Hodrea, J., Hosszu, A., Koszegi, S., Zelena, D., Balogh, D., et al. (2016). The role of sigma-1 receptor and brain-derived neurotrophic factor in the development of diabetes and comorbid depression in streptozotocin-induced diabetic rats. Psychopharmacology (Berl). 233 (7), 1269–1278. doi:10.1007/s00213-016-4209-x
Lepine, J. P., and Briley, M. (2011). The increasing burden of depression. Neuropsychiatric Dis. Treat. 7 (1), 3–7. doi:10.2147/NDT.S19617
Li, C. W., Deng, M. Z., Gao, Z. J., Dang, Y. Y., Zheng, G. D., Yang, X. J., et al. (2020). Effects of compound K, a metabolite of ginsenosides, on memory and cognitive dysfunction in db/db mice involve the inhibition of ER stress and the NLRP3 inflammasome pathway. Food Funct. 11 (5), 4416–4427. doi:10.1039/c9fo02602a
Li, D., Chen, W., Zhu, X., and Liu, Y. (2018). Research progress of diabetes mellitus complicated with depression. Med. Information. 31 (14), 20–23. doi:10.3969/j.issn.1006-1959.2018.14.008
Li, X. (2017). Clinical experience of shugan jianpi therapy in diabetes combined with depression. China’s Naturopathy. 25 (7), 47–48. doi:10.19621/j.cnki.11-3555/r.2017.07.036
Li, Z., Guo, X., Jiang, H., Sun, G., Sun, Y., and Abraham, M. R. (2016). Diagnosed but not undiagnosed diabetes is associated with depression in rural areas. Int. J. Environ. Res. Publ. Health. 13 (11). doi:10.3390/ijerph13111136
Lim, G. Y., Tam, W. W., Lu, Y., Ho, C. S., Zhang, M. W., and Ho, R. C. (2018). Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci. Rep. 8 (1), 2861. doi:10.1038/s41598-018-21243-x
Lindqvist, D., Dhabhar, F. S., James, S. J., Hough, C. M., Jain, F. A., Bersani, F. S., et al. (2017). Oxidative stress, inflammation and treatment response in major depression. Psychoneuroendocrinology. 76, 197–205. doi:10.1016/j.psyneuen.2016.11.031
Lu, W. (2012). Research on the Symptomatology of Diabetes with Depression and Clinical Evaluation of Yishen Jieyu Decoction Treatment. Beijing, China: Beijing University of Chinese Medicine
Lu, Y., Ma, X., Kong, Q., Xu, Y., Hu, J., Wang, F., et al. (2019). Novel dual-color drug screening model for GLUT4 translocation in adipocytes. Mol. Cell. Probes. 43, 6–12. doi:10.1016/j.mcp.2019.01.002
Luc, K., Schramm-Luc, A., Guzik, T. J., and Mikolajczyk, T. P. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. J. Physiol. Pharmacol. 70 (6), 809–824. doi:10.26402/jpp.2019.6.01
Luo, C., Ke, Y., Yuan, Y., Zhao, M., Wang, F., Zhang, Y., et al. (2016). A novel herbal treatment reduces depressive-like behaviors and increases brain-derived neurotrophic factor levels in the brain of type 2 diabetic rats. Neuropsychiatric Dis. Treat. 12, 3051–3059. doi:10.2147/NDT.S117337
Ma, K., Zhang, H., Wang, S., Wang, H., Wang, Y., Liu, J., et al. (2019). The molecular mechanism underlying GABAergic dysfunction in nucleus accumbens of depression-like behaviours in mice. J. Cell Mol. Med. 23 (10), 7021–7028. doi:10.1111/jcmm.14596
Mahar, I., Bambico, F. R., Mechawar, N., and Nobrega, J. N. (2014). Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci. Biobehav. Rev. 38, 173–192. doi:10.1016/j.neubiorev.2013.11.009
Mehta, V., Parashar, A., Sharma, A., Singh, T. R., and Udayabanu, M. (2017). Quercetin ameliorates chronic unpredicted stress-mediated memory dysfunction in male Swiss albino mice by attenuating insulin resistance and elevating hippocampal GLUT4 levels independent of insulin receptor expression. Horm. Behav. 89, 13–22. doi:10.1016/j.yhbeh.2016.12.012
Meijer, O. C., Koorneef, L. L., and Kroon, J. (2018). Glucocorticoid receptor modulators. Ann. Endocrinol. 79 (3), 107–111. doi:10.1016/j.ando.2018.03.004
Mezuk, B., Eaton, W. W., Albrecht, S., and Golden, S. H. (2008). Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 31 (12), 2383–2390. doi:10.2337/dc08-0985
Moulton, C. D., Pickup, J. C., and Ismail, K. (2015). The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 3 (6), 461–471. doi:10.1016/S2213-8587(15)00134-5
Mukherjee, N., and Chaturvedi, S. K. (2019). Depressive symptoms and disorders in type 2 diabetes mellitus. Curr. Opin. Psychiatr. 32 (5), 416–421. doi:10.1097/YCO.0000000000000528
Myint, A. M., Leonard, B. E., Steinbusch, H. W., and Kim, Y. K. (2005). Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 88 (2), 167–173. doi:10.1016/j.jad.2005.07.008
Nouwen, A., Adriaanse, M. C., van Dam, K., Iversen, M. M., Viechtbauer, W., Peyrot, M., et al. (2019). Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. Diabet. Med. 36 (12), 1562–1572. doi:10.1111/dme.14054
Papazoglou, I. K., Jean, A., Gertler, A., Taouis, M., and Vacher, C. M. (2015). Hippocampal GSK3beta as a molecular link between obesity and depression. Mol. Neurobiol. 52 (1), 363–374. doi:10.1007/s12035-014-8863-x
Patel, S. S., Ray, R. S., Sharma, A., Mehta, V., Katyal, A., and Udayabanu, M. (2018). Antidepressant and anxiolytic like effects of Urtica dioica leaves in streptozotocin induced diabetic mice. Metab. Brain Dis. 33 (4), 1281–1292. doi:10.1007/s11011-018-0243-1
Patel, S. S., and Udayabanu, M. (2014). Urtica dioica extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced diabetic mice. Metab. Brain Dis. 29 (1), 121–130. doi:10.1007/s11011-014-9480-0
Petrak, F., Baumeister, H., Skinner, T. C., Brown, A., and Holt, R. I. G. (2015). Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol. 3 (6), 472–485. doi:10.1016/S2213-8587(15)00045-5
Porte, D., Baskin, D. G., and Schwartz, M. W. (2002). Leptin and insulin action in the central nervous system. Nutr. Rev. 60(10), S20–S29. doi:10.1301/002966402320634797
Pradeepa, R., and Mohan, V. (2017). Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur. J. Clin. Nutr. 71 (7), 816–824. doi:10.1038/ejcn.2017.40
Rahmani, G., Farajdokht, F., Mohaddes, G., Babri, S., Ebrahimi, V., and Ebrahimi, H. (2020). Garlic (Allium sativum) improves anxiety- and depressive-related behaviors and brain oxidative stress in diabetic rats. Arch. Physiol. Biochem. 126 (2), 95–100. doi:10.1080/13813455.2018.1494746
Reus, G. Z., Carlessi, A. S., Silva, R. H., Ceretta, L. B., and Quevedo, J. (2019). Relationship of oxidative stress as a link between diabetes mellitus and major depressive disorder. Oxid. Med. Cell Longev. 2019, 8637970. doi:10.1155/2019/8637970
Reus, G. Z., Dos Santos, M. A., Abelaira, H. M., Titus, S. E., Carlessi, A. S., Matias, B. I., et al. (2016). Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behaviour and reduces oxidative stress in brain and pancreas. Diabetes Metab. Res. Rev. 32 (3), 278–288. doi:10.1002/dmrr.2732
Rhyu, Y. A., Jang, J. Y., Park, S., An, J. H., Kim, D. L., Kim, S. K., et al. (2019). Impaired cortisol and growth hormone counterregulatory responses among severe hypoglycemic patients with type 2 diabetes mellitus. Endocrinol Metab. (Seoul). 34 (2), 187–194. doi:10.3803/EnM.2019.34.2.187
Roshan, B., and Stanton, R. C. (2013). A story of microalbuminuria and diabetic nephropathy. J. Nephropathol. 2 (4), 234–240. doi:10.12860/JNP.2013.37
Rubin, R. R., Ma, Y., Marrero, D. G., Peyrot, M., Barrett-Connor, E. L., Kahn, S. E., et al. (2008). Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 31 (3), 420–426. doi:10.2337/dc07-1827
Sadigh-Eteghad, S., Tayefi-Nasrabadi, H., Aghdam, Z., Zarredar, H., Shanehbandi, D., Khayyat, L., et al. (2011). Rosa canina L. Fruit hydro-alcoholic extract effects on some immunological and biochemical parameters in rats. Bioimpacts. 1 (4), 219–224. doi:10.5681/bi.2011.031
Sahin, T. D., Gocmez, S. S., Eraldemir, F. C., and Utkan, T. (2019). Anxiolytic-like and antidepressant-like effects of resveratrol in streptozotocin-induced diabetic rats. Noro Psikiyatr Ars. 56 (2), 144–149. doi:10.29399/npa.23176
Sauter, N. S., Thienel, C., Plutino, Y., Kampe, K., Dror, E., Traub, S., et al. (2015). Angiotensin II induces interleukin-1beta-mediated islet inflammation and beta-cell dysfunction independently of vasoconstrictive effects. Diabetes. 64 (4), 1273–1283. doi:10.2337/db14-1282
Shen, J. D., Wei, Y., Li, Y. J., Qiao, J. Y., and Li, Y. C. (2017). Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. Metab. Brain Dis. 32 (4), 1163–1172. doi:10.1007/s11011-017-0017-1
Shirazi, S. N., Friedman, A. R., Kaufer, D., and Sakhai, S. A. (2015). Glucocorticoids and the brain: neural mechanisms regulating the stress response. Adv. Exp. Med. Biol. 872, 235–252. doi:10.1007/978-1-4939-2895-8_10
Shivavedi, N., Charan Tej, G. N. V., Neogi, K., and Nayak, P. K. (2019). Ascorbic acid therapy: a potential strategy against comorbid depression-like behavior in streptozotocin-nicotinamide-induced diabetic rats. Biomed. Pharmacother. 109, 351–359. doi:10.1016/j.biopha.2018.10.070
Strine, T. W., Mokdad, A. H., Dube, S. R., Balluz, L. S., Gonzalez, O., Berry, J. T., et al. (2008). The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen. Hosp. Psychiatr. 30 (2), 127–137. doi:10.1016/j.genhosppsych.2007.12.008
Su, Q., Tao, W., Wang, H., Chen, Y., Huang, H., and Chen, G. (2016). Umbelliferone attenuates unpredictable chronic mild stress induced-insulin resistance in rats. IUBMB Life. 68 (5), 403–409. doi:10.1002/iub.1496
Tabatabaei, S. R. F., Ghaderi, S., Bahrami-Tapehebur, M., Farbood, Y., and Rashno, M. (2017). Aloe vera gel improves behavioral deficits and oxidative status in streptozotocin-induced diabetic rats. Biomed. Pharmacother. 96, 279–290. doi:10.1016/j.biopha.2017.09.146
Thakur, A. K., Chatterjee, S. S., and Kumar, V. (2014). Antidepressant-like effects of Brassica juncea L. leaves in diabetic rodents. Indian J. Exp. Biol. 52 (6), 613–622
Tusa, B. S., Alemayehu, M., Weldesenbet, A. B., Kebede, S. A., and Dagne, G. A. (2020). Prevalence of depression and associated factors among diabetes patients in east shewa, Ethiopia: bayesian approach. Depress Res Treat. 2020, 4071575. doi:10.1155/2020/4071575
Wang, J., Duan, P., Cui, Y., Li, Q., and Shi, Y. (2016). Geniposide alleviates depression-like behavior via enhancing BDNF expression in hippocampus of streptozotocin-evoked mice. Metab. Brain Dis. 31 (5), 1113–1122. doi:10.1007/s11011-016-9856-4
Wang, J., Zhao, X., and He, M. (2012a). Is BDNF biological link between depression and type 2 diabetes mellitus?. Med. Hypotheses. 79 (2), 255–258. doi:10.1016/j.mehy.2012.05.002
Wang, Y., Fan, R., and Huang, X. (2012b). Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression. J. Ethnopharmacol. 141 (2), 571–577. doi:10.1016/j.jep.2011.08.079
Wang, R. (2008). Clinical Study on Treating Diabetes Mellitus Combined with Depression with Shu Gan Jian Pi Jie Yu Formular. Jinan, China: Shandong University of Traditional Chinese Medicine
Wang, W., Sun, Y., Zhong, Q., Liu, Y., and Xue, M. (2020a). Interventional effect of danggui buxue decoction on serum inflammatory factors in diabetic model rats. Acta Chinese Medicine. 6 (35), 1258–1261. doi:10.16368/j.issn.1674-8999.2020.06.284
Wang, W., Zhang, W., Sun, Y., Zhong, Q., and Xue, M. (2020b). Effects of danggui buxue decoction and its main active ingredient ferulic acid on CUMS model GK rats. Tradit. Chin. Drug Res. Clin. Pharmacol. 31 (6), 649–654. doi:10.19378/j.issn.1003-9783.2020.06.005
Wang, W., Zhang, L., Sun, Y., and Xue, M. (2018). Research progress of treatment of danggui buxue decoction on diabetes mellitus with depression. World Sci. Tech./Modernization of Tradit. Chin. Med. Materia Medica. 20 (12), 2191–2195. doi:10.11842/wst.2018.12.016
Wang, X., Lou, Y., and Gao, Z. (2013). Effects of danzhi xiaoyao power on IRS-2-PI3K signaling pathway in liver tissues on diabetes mellitus rats with depression. Chin. Archives of Tradit. Chin. Med. 31 (11), 2450–2452. doi:10.13193/j.issn.1673-7717.2013.11.052
Wang, Y. H., Yin, L. T., Yang, H., Li, X. L., and Wu, K. G. (2014). Hypoglycemic and anti-depressant effects of Zuogui Jiangtang Jieyu formulation in a model of unpredictable chronic mild stress in rats with diabetes mellitus. Exp. Ther. Med. 8 (1), 281–285. doi:10.3892/etm.2014.1681
Wang, Y., Yang, H., Li, W., Meng, P., Han, Y., Zhang, X., et al. (2015). Zuogui jiangtang jieyu formulation prevents hyperglycaemia and depressive-like behaviour in rats by reducing the glucocorticoid level in plasma and Hippocampus. Evid. Based Complement Alternat. Med. 2015, 158361. doi:10.1155/2015/158361
Yang, H., Han, Y., Liu, Z., Meng, P., Du, Q., Zhao, H., et al. (2019). Effect of zuogui jiangtang jieyu formulation on signaling pathway in hypothalamus of diabetic rats with depression. Chin. J. Modern Applied Pharmacy. 36 (11), 1333–1337. doi:10.13748/j.cnki.issn1007-7693.2019.11.004
Yang, H., Liu, J., Tang, L., Lin, X., Luo, W., Han, Y., et al. (2020). Effects of Zuogui Jiangtang Jieyu Formulation on insulin resistance in hipppocampus of rats with diabetes-related depression. Chin. Tradit. Herb. Drugs. 52 (11), 3013–3020. doi:10.7501/j.issn.0253-2670.2020.11.020
Yang, H., Wang, Y., Meng, P., Liu, Z., Liu, J., Yang, Q., et al. (2018). Effects of zuogui jiangtang jieyu decoction on hippocampal chemokine CX3C receptor 1 and neuroinflammatory factors in Hippocampus of diabetic rats with depression. J. Tradit. Chin. Med. 59 (20), 1783–1787. doi:10.13288/j.11-2166/r.2018.20.015
Yaribeygi, H., Farrokhi, F. R., Butler, A. E., and Sahebkar, A. (2019). Insulin resistance: review of the underlying molecular mechanisms. J. Cell. Physiol. 234 (6), 8152–8161. doi:10.1002/jcp.27603
Ye, M., Ke, Y., Liu, B., Yuan, Y., Wang, F., Bu, S., et al. (2017). Root bark of Morus alba ameliorates the depressive-like behaviors in diabetic rats. Neurosci. Lett. 637, 136–141. doi:10.1016/j.neulet.2016.11.036
Ye, T., Meng, X., Wang, R., Zhang, C., He, S., Sun, G., et al. (2018). Gastrodin alleviates cognitive dysfunction and depressive-like behaviors by inhibiting ER stress and NLRP3 inflammasome activation in db/db mice. Int. J. Mol. Sci. 19 (12). doi:10.3390/ijms19123977
Yi, S. S., Hwang, I. K., Shin, J. H., Choi, J. H., Lee, C. H., Kim, I. Y., et al. (2010). Regulatory mechanism of hypothalamo-pituitary-adrenal (HPA) axis and neuronal changes after adrenalectomy in type 2 diabetes. J. Chem. Neuroanat. 40 (2), 130–139. doi:10.1016/j.jchemneu.2010.05.003
Yohn, C. N., Gergues, M. M., and Samuels, B. A. (2017). The role of 5-HT receptors in depression. Mol. Brain. 10 (1), 28. doi:10.1186/s13041-017-0306-y
Yu, M., Zhang, X., Lu, F., and Fang, L. (2015). Depression and risk for diabetes: a meta-analysis. Can. J. Diabetes. 39 (4), 266–272. doi:10.1016/j.jcjd.2014.11.006
Zemdegs, J., Martin, H., Pintana, H., Bullich, S., Manta, S., Marques, M. A., et al. (2019). Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J. Neurosci. 39 (30), 5935–5948. doi:10.1523/JNEUROSCI.2904-18.2019
Zhang, H., Chi, X., Pan, W., Wang, S., Zhang, Z., Zhao, H., et al. (2020). Antidepressant mechanism of classical herbal formula lily bulb and Rehmannia decoction: insights from gene expression profile of medial prefrontal cortex of mice with stress-induced depression-like behavior. Gene Brain Behav. 19 (5), e12649. doi:10.1111/gbb.12649
Zhang, M., and Xiao, W. (2008). Clinical observation on the treatment of diabetes and depression with modified danzhi xiaoyao powder. J. Liaoning Univ. Tradi. Chin. Med. 10 (2), 108–109. doi:10.13194/j.jlunivtcm.2008.02.110.zhangm.053
Zhang, W., Cheng, H., and Feng, X. (2017). Danzhi xiaoyao powder (丹栀逍遥散) adjustment on the treatment of type 2 diabetes mellitus complicating depression: a meta-analysis. Guiding J. Tradi. Chin. Med. Pharmacology. 23 (23), 63–67. doi:10.13862/j.cnki.cn43-1446/r.2017.23.018
Zhang, W., and Feng, X. (2016). Summary of traditional Chinese medicine on the treatment of diabetes mellitus complicating depression. Chi. J. Tradi. Chin. Med. Pharmacy. 31 (4), 1374–1376
Zhao, F., Siu, J. J., Huang, W., Askwith, C., and Cao, L. (2019). Insulin modulates excitatory synaptic transmission and synaptic plasticity in the mouse Hippocampus. Neuroscience. 411, 237–254. doi:10.1016/j.neuroscience.2019.05.033
Zheng, W., Wang, G., Zhang, Z., Wang, Z., and Ma, K. (2020). Research progress on classical traditional Chinese medicine formula Liuwei Dihuang pills in the treatment of type 2 diabetes. Biomed. Pharmacother. 121, 109564. doi:10.1016/j.biopha.2019.109564
Zhou, X., Gan, T., Fang, G., Wang, S., Mao, Y., and Ying, C. (2018). Zeaxanthin improved diabetes-induced anxiety and depression through inhibiting inflammation in hippocampus. Metab. Brain Dis. 33 (3), 705–711. doi:10.1007/s11011-017-0179-x
Keywords: depression, diabetes, comorbidity, natural products, TCM
Citation: Lu Y, An T, Tian H, Gao X, Wang F, Wang S and Ma K (2021) Depression with Comorbid Diabetes: What Evidence Exists for Treatments Using Traditional Chinese Medicine and Natural Products?. Front. Pharmacol. 11:596362. doi: 10.3389/fphar.2020.596362
Received: 20 August 2020; Accepted: 14 December 2020;
Published: 25 January 2021.
Edited by:
George Qian Li, Western Sydney University, AustraliaCopyright © 2021 Lu, An, Tian, Gao, Wang, Wang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Furong Wang, 15168888786@163.com; Shijun Wang, pathology@163.com; Ke Ma, make19880710@163.com
†These authors have contributed equally to this work and share co-first authorship